Indivior logo

INDV - Indivior News Story

148.6p -4.4  -2.9%

Last Trade - 8:34am

Market Cap £1.12bn
Enterprise Value £654.4m
Revenue £477.3m
Position in Universe 409th / 1828

Indivior PLC - J.P. Morgan Healthcare Conference

Thu 4th January, 2018 1:00pm
RNS Number : 8852A
Indivior PLC
04 January 2018

Indivior's Shaun Thaxter to Present at the 36thAnnual

J.P. Morgan Healthcare Conference on January 11th

Slough, UK, and Richmond, VA, 4th January 2018 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will present at the 36thAnnual J.P. Morgan Healthcare Conference on January 11th, 2018, at 8:30 a.m. local Pacific time (11:30 a.m. Eastern / 4:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. Mark Crossley, CFO, and Jason Thompson, VP of Investor Relations, will also be in attendance. Thaxter will review Indivior's business and outlook. The presentation will be webcast live and, along with the presentation materials, will be available to the public on the "Investors" section of Indivior's website (

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more.


Jason Thompson

Vice President, Investor Relations

Tel: 804-423-8916 or

This information is provided by RNS
The company news service from the London Stock Exchange
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.